<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04957953</url>
  </required_header>
  <id_info>
    <org_study_id>69HCL21_0627</org_study_id>
    <secondary_id>2021-A01523-38</secondary_id>
    <nct_id>NCT04957953</nct_id>
  </id_info>
  <brief_title>Pregnant Women Vaccinated Against Covid-19.</brief_title>
  <acronym>COVACPREG</acronym>
  <official_title>Prospective Cohort of Pregnant Women Vaccinated Against Covid-19.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospices Civils de Lyon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospices Civils de Lyon</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Establish a cohort of pregnant women exposed to a COVID19 vaccine, whether or not they have&#xD;
      experienced an adverse event, to assess the potential effects of vaccines on the course of&#xD;
      pregnancy, on the fetus or newborn and on the mother.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 1, 2021</start_date>
  <completion_date type="Anticipated">March 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>To assess the potential effects of vaccines on the course of pregnancy.</measure>
    <time_frame>One month after injection</time_frame>
    <description>Pregnancy outcomes including the rate of spontaneous miscarriage, fetal death in utero, stillbirth</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To assess the potential effects of vaccines on the fetus or newborn</measure>
    <time_frame>One month after injection</time_frame>
    <description>Characteristics of newborns (weight, height etc.) Malformation rate</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To assess the potential effects of vaccines on the mother.</measure>
    <time_frame>One month after injection</time_frame>
    <description>Rates and types of adverse events following vaccination in pregnant women vaccinated against COVID 19</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">2250</enrollment>
  <condition>Pregnant Women Vaccinated Against Covid-19</condition>
  <arm_group>
    <arm_group_label>Pregnant Women Vaccinated against Covid-19</arm_group_label>
    <description>Woman over 18 years of age who has received at least one Covid-19 vaccine during her pregnancy, regardless of the trimester of pregnancy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Patient's consent</intervention_name>
    <description>Primary enrolment will be carried out at the time of vaccination at the main vaccination sites, with the patient's consent. The agreement form filled in online includes the surname, first name, month and year of birth. This form serves as an agreement to participate in the study.</description>
    <arm_group_label>Pregnant Women Vaccinated against Covid-19</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Inclusion form</intervention_name>
    <description>This form includes the date of the last menstrual period, vaccination data (type of vaccine, date of vaccination, 1st or 2nd injection, etc.), socio-demographic data of the pregnant woman, medical and surgical history, gynaecological and obstetrical history, a description of the current pregnancy, and the medication taken by the patient during her pregnancy....&#xD;
A link to complete this form (with the unique identifier) will be sent to each woman included who has given her consent to participate.</description>
    <arm_group_label>Pregnant Women Vaccinated against Covid-19</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Adverse reaction report form.</intervention_name>
    <description>One month after each injection of the vaccine, information will be collected on any vaccination-related adverse reactions that may impact the pregnancy (fever, hypertension, etc.) or on the onset of a Covid-19 infection,</description>
    <arm_group_label>Pregnant Women Vaccinated against Covid-19</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Follow-up report form.</intervention_name>
    <description>In the 2 months following the expected delivery date, information will be collected on the outcome of the pregnancy (delivery, spontaneous abortion, etc.) and maternal clinical signs (pre-eclampsia, gestational hypertension, gestational diabetes, etc.). Before sending the link to this form, information will be sent to the second holder of parental authority. In the absence of opposition, data on the newborn will be collected (sex, height, weight, head circumference, Apgar, malformation, neonatal pathology, etc.)</description>
    <arm_group_label>Pregnant Women Vaccinated against Covid-19</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Any pregnant woman who has received at least one Covid-19 vaccine during her pregnancy,&#xD;
        regardless of the trimester of pregnancy.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient aged 18 years and over,&#xD;
&#xD;
          -  Pregnant,&#xD;
&#xD;
          -  Vaccinated against COVID-19,&#xD;
&#xD;
          -  Not having expressed any objection to inclusion in the cohort&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  No agreement at inclusion,&#xD;
&#xD;
          -  Age under 18 years&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Judith COTTIN</last_name>
    <role>Principal Investigator</role>
    <affiliation>Service Hospitalo-Universitaire de Pharmacotoxicologie</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Judith COTTIN</last_name>
    <phone>04 72 11 94 11</phone>
    <email>judith.cottin@chu-lyon.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Isabelle LACROIX</last_name>
    <phone>05 61 14 59 77</phone>
    <email>isabelle.lacroix@univ-tlse3.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Service Hospitalo-Universitaire de Pharmacotoxicologie</name>
      <address>
        <city>Lyon</city>
        <zip>69424</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Judith COTTIN</last_name>
      <phone>04 72 11 94 11</phone>
      <email>judith.cottin@chu-lyon.fr</email>
    </contact>
    <investigator>
      <last_name>Isabelle LACROIX</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>July 7, 2021</study_first_submitted>
  <study_first_submitted_qc>July 8, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 12, 2021</study_first_posted>
  <last_update_submitted>October 12, 2021</last_update_submitted>
  <last_update_submitted_qc>October 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

